Filing Details
- Accession Number:
- 0000899243-23-020082
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-10-31 21:43:04
- Reporting Period:
- 2023-10-27
- Accepted Time:
- 2023-10-31 21:43:04
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1609809 | Seres Therapeutics Inc. | MCRB | Pharmaceutical Preparations (2834) | 274326290 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1744682 | Paula Cloghessy | C/O Seres Therapeutics, Inc. 200 Sidney Street Cambridge 02139 | See Remarks | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-10-27 | 9,418 | $0.00 | 48,588 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-10-30 | 2,904 | $1.35 | 45,684 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Restricted Stock Units | Acquisiton | 2023-04-27 | 18,835 | $0.00 | 18,835 | $0.00 |
| Common Stock | Restricted Stock Units | Disposition | 2023-10-27 | 9,418 | $0.00 | 9,418 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 18,835 | No | 4 | A | Direct | ||
| 9,417 | No | 4 | M | Direct |
Footnotes
- On February 3, 2023, the reporting person was granted an award of 18,835 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 9,418 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 9,417 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date.
- Includes 7,424 shares of common stock acquired under the Issuer's employee stock purchase plan.
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 17, 2023, solely with the intent to cover taxes in connection with the vesting of the RSUs.
- The price reported in column 4 is a weighted average of the price. These shares were sold in multiple transactions at prices ranging from $1.35 to $1.3614, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date.
Billionaire Hedge Funds
